Open Access. Powered by Scholars. Published by Universities.®
Zucker School of Medicine at Hofstra/Northwell
Calcium-channel antagonist;; double-blind;; druggable genome;; negative;; symptoms;; add-on;; psychiatric-disorders;; adjunctive treatment;; tardive-dyskinesia;; wide association;; drug discovery;; Biochemistry & Molecular Biology;; Neurosciences & Neurology;; Psychiatry
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Targeting The Schizophrenia Genome: A Fast Track Strategy From Gwas To Clinic, T. Lencz, A. K. Malhotra
Targeting The Schizophrenia Genome: A Fast Track Strategy From Gwas To Clinic, T. Lencz, A. K. Malhotra
Journal Articles
The Psychiatric Genomics Consortium-Schizophrenia Workgroup (PGC-SCZ) has recently published a genomewide association study (GWAS) identifying > 100 genetic loci, encompassing a total of 341 protein-coding genes, attaining genomewide significance for susceptibility to schizophrenia. Given the extremely long time (12-15 years) and expense (>$1 billion) associated with the development of novel drug targets, repurposing of drugs with known and validated targets may be the most expeditious path toward deriving clinical utility from these GWAS findings. In the present study, we examined all genes within loci implicated by the PGC-SCZ GWAS against databases of targets of both approved and registered pharmaceutical compounds. …